Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400952 · ClinicalTrials.gov registry record · Phase 2
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
A Phase 2 study of Keratoconus, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07400952: Recruiting Phase 2 study of Keratoconus, sponsored by Glaukos Corporation.
NCT07400952 is a Phase 2 study of Keratoconus that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 100 participants, below the 1,176-participant average among 21 other Keratoconus trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07400952, a Phase 2 study of Keratoconus, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Primary Outcome
Mean change from baseline in maximum corneal curvature
Conditions Studied
Interventions
- DRUG GLK-221 Ophthalmic Solution
- DRUG Placebo Ophthalmic Solution
Study Locations (1)
Ohio
- Glaukos Clinical Study Site - Westerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-12-23 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT07400952 shows while recruiting
NCT07400952 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,176-participant average among 21 other Keratoconus trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Keratoconus appearing as the primary indexed condition, and to 2 interventions - of which GLK-221 Ophthalmic Solution is the first listed.
NCT07400952 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07400952 about?
NCT07400952 is a clinical study titled "Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus". Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
What is the current status of trial NCT07400952?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-12-23. Estimated completion is 2027-04.
What conditions does trial NCT07400952 study?
This clinical trial studies the following conditions: Keratoconus.
What interventions are being tested in trial NCT07400952?
The interventions under investigation include: GLK-221 Ophthalmic Solution (DRUG), Placebo Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT07400952?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400952 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07400952's enrollment target sits among peer trials
100 14th of 21 higher than 5 of 21 other Keratoconus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keratoconus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning
RECRUITING · Phase 2
-
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
RECRUITING · Phase 2
-
Comparison of Standard vs. Accelerated Corneal Crosslinking
RECRUITING · Phase 2
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI